R&D Going wide on immune system activation, with Jeffrey Meckler Indaptus CEO Jeff Meckler discusses his company's unconventional approach to immunotherapy, based on activating a wide swath of the immune system.
R&D Reuters Pharma USA 2024 – Jeffrey Meckler Most of the exciting work being done right now in cancer immunotherapy is centred on highly targeted approaches that aim to activate only the most necessary immune responses to eliminate a